Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
•
Thoracic Surgery
How do you decide which local consolidative therapy to offer for a single lung metastasis in a patient with metastatic colorectal cancer?
(ie. surgery vs SBRT)
Answer from: Radiation Oncologist at Community Practice
SBRT, then more chemotherapy.
Sign in or Register to read more
6461
Related Questions
What constraints do you use for the BID small cell lung cancer regimen?
How are you incorporating Tumor Treating Fields for locally progressive/metastatic NSCLC, if at all?
Is there a chest wall constraint you typically use for 60 Gy in 15 fraction NSCLC treatment?
What is your planning approach for SBRT when the tumor abuts the great vessels such as aortic arch or SVC?
Do you have different hotspot and heterogeneity goals for SBRT of ground glass lesions vs more solid adenocarcinoma NSCLC lesions?
For NSCLC patients treated with neoadjuvant chemoimmunotherapy and surgery with ypN2 disease, what factors would cause you to recommend PORT?
Would you offer lung SBRT in a patient with Pulmonary Langerhans Cell Histiocytosis (PLCH)?
Would you consider omission of PORT for node+ NSCLC with a positive margin in the setting of a high tumor PD-L1 score and plans for immunotherapy?
In a patient with node-positive limited-stage small cell lung cancer, how do you approach radiation in a patient whose small primary tumor resolves after one cycle of chemotherapy?
Given the findings of SUNSET, demonstrating 60 Gy in 8 fractions to be a safe and effective regimen for ultracentral lesions, in what situations would you elect to use a 10 fraction hypofractionated regimen?